PFE and MRK Related Headlines
Go Back- Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight
- Large cap pharma defensive AI winner, says RBC as it backs Lilly & AbbVie
- Barclays launches U.S. biopharma coverage with four preferred picks
- Trump to announce prescription drug price agreements
- Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now
- Vaccine stocks brace for shock waves at this week’s ACIP meeting
- UK and US poised to agree zero-tariffs deal on pharmaceuticals - The Times
- FDA approves Padcev plus Keytruda for certain patients with bladder cancer
- FDA approves Keytruda and Padcev combo for bladder cancer treatment
- US Pausing Pharma Duties While Negotiations Ongoing - Politico
- Trump on deal with Pfizer: we're going to be paying the lowest price, other drugmakers will commit in coming weeks
- Trump says we’ll be reducing prices (of drugs) by a 100% and in some cases more
- Bernstein on AmericasMedicines.com: 'The Noise Starts, But Not (Yet) from Trump'
- Raymond James Comments on FDA and HHS Reforms for DTC Pharma Advertising
- Trump demands pharma CEOs lower drug prices within 60 days
- Trump Posts Letters to Regeneron, Merck, AstraZeneca, GSK, Pfizer, Novo Nordisk, Amgen, Bristol-Myears, AbbVie, Novartis, Gilead, J&J on Truth Social
- Jefferies: 'We highlight multiple de-risked or commercial-stage names that we think have promising M&A potential'
- Lawmakers push to ban direct-to-consumer drug advertising, WSJ reports
- BMO Capital: ACIP Cuts a Broad Negative To the Vaccine Space
PFE and MRK Related Press Releases
Go Back- Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight
- Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now
